IDL-2965

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameIDL-2965

Drug Alias NameIDL-2965

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionIntegrin alpha-V/beta-1 inhibitorsIntegrin alpha-V/beta-6 antagonistsIntegrin alpha-V/beta-3 antagonists

TargetsIntegrin alpha-V/beta-1Integrin alpha-V/beta-6Integrin alpha-V/beta-3

Therapy Area/IndicationsIdiopathic Pulmonary FibrosisMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsIdiopathic Pulmonary Fibrosis

ATC CodeN/A